|
CEP97 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.55529999990023E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.87419999981331E-07 |
| Normal-vs-Stage2 |
1.56729999999383E-05 |
| Normal-vs-Stage3 |
1.62479996124176E-09 |
| Normal-vs-Stage4 |
3.09550000077152E-08 |
| Stage1-vs-Stage2 |
3.754200E-01 |
| Stage1-vs-Stage3 |
3.717700E-02 |
| Stage1-vs-Stage4 |
2.878400E-02 |
| Stage2-vs-Stage3 |
5.274800E-01 |
| Stage2-vs-Stage4 |
4.231600E-01 |
| Stage3-vs-Stage4 |
8.043000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.76610004398725E-09 |
| Normal-vs-AfricanAmerican |
6.555900E-03 |
| Normal-vs-Asian |
1.97226999999467E-05 |
| Caucasian-vs-AfricanAmerican |
3.411000E-01 |
| Caucasian-vs-Asian |
9.530000E-01 |
| AfricanAmerican-vs-Asian |
4.153600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.1490999807815E-09 |
| Normal-vs-Female |
1.1445000003274E-07 |
| Male-vs-Female |
1.216460E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.22829999999763E-05 |
| Normal-vs-Age(41-60Yrs) |
1.16510001646475E-09 |
| Normal-vs-Age(61-80Yrs) |
4.17080003867198E-09 |
| Normal-vs-Age(81-100Yrs) |
8.397700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.653610E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.037800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.021400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.787000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.156400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.962600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.422200E-02 |
| Classical-VS-Follicular |
1.272810E-01 |
| Classical-VS-Other |
1.625570E-01 |
| Classical-VS-Normal |
1.82269999982054E-07 |
| Tall-VS-Follicular |
2.716400E-01 |
| Tall-VS-Other |
7.255200E-01 |
| Tall-VS-Normal |
1.00039999950674E-07 |
| Follicular-VS-Other |
4.340200E-01 |
| Follicular-VS-Normal |
5.57090000019578E-07 |
| Other-VS-Normal |
2.479300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.89350002133671E-09 |
| Normal-vs-N1 |
4.57600000003389E-07 |
| N0-vs-N1 |
6.833200E-01 |
|
|
